Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACACB | O00763 | 1/20 | 0.35 |
| ▸ | CNR1 | P21554 | 1/20 | 0.34 |
| ▸ | CNR2 | P34972 | 1/20 | 0.34 |
| ▸ | HSD17B1 | P14061 | 1/20 | 0.32 |
| ▸ | HSD17B2 | P37059 | 1/20 | 0.32 |
| ▸ | AKT1 | P31749 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25863741 | 0.86 | ACACB (0.37) | ACACBCNR1CNR2HSD17B1HSD17B2 | |
| SCHEMBL23558336 | 0.79 | CNR1 (0.35) | ACACBCNR1CNR2HSD17B1HSD17B2 | |
| SCHEMBL23558464 | 0.78 | ACACB (0.37) | ACACBHSD17B1HSD17B2 | |
| SCHEMBL23558300 | 0.76 | PPM1D (0.37) | ACACBCNR1CNR2AKT1 | |
| SCHEMBL23558357 | 0.72 | KDM4E (0.37) | ACACBHSD17B1HSD17B2KDM4E | |
| SCHEMBL30355740 | 0.71 | MAPT (0.43) | CNR1CNR2AKT1MAPTKDM4E | |
| SCHEMBL23523871 | 0.71 | MAPT (0.43) | CNR1CNR2AKT1MAPTKDM4E | |
| SCHEMBL30355583 | 0.71 | NPC1 (0.47) | CNR1CNR2MAPTKDM4E | |
| SCHEMBL23523733 | 0.71 | NPC1 (0.47) | CNR1CNR2MAPTKDM4E | |
| SCHEMBL23523716 | 0.70 | NPC1 (0.43) | MAPTKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230234946-A1 | COMPOUNDS FOR MODULATING S1P1 ACTIVITY AND METHODS OF USING THE SAME | TREVENA, INC. | 2023-07-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230234946-A1 | COMPOUNDS FOR MODULATING S1P1 ACTIVITY AND METHODS OF USING THE SAME | S1PR1, S1PR2, S1PR3 | ACACB 3779/4885CNR1 20/4885CNR2 38/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.